Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study is to assess the role of adjuvant therapy in stage I-III gallbladder cancer (GBC) patients who have undergone R0 resection. Materials and Methods Clinical data were collected on 441 consecutive patients who underwent R0 resection for stage I-III GBC. Eligible patients were classified into adjuvant therapy and surveillance only groups. Propensity score matching (PSM) between the two groups was performed, adjusting clinical factors. Results In total, 84 and 279 patients treated with adjuvant therapy and followed up with surveillance only, respectively, were included in the analysis. Before PSM, the 5-year relapse-free survival (RFS) rate was lower in the adjuvant therapy group than in the surveillance only group (50.8% vs. 74.8%, p < 0.001), although there was no statistically significant difference in the 5-year overall survival (OS) rate (66.2% vs. 79.5%, p=0.089). After the PSM, baseline characteristics became comparable and there were no differences in the 5-year RFS (50.8% vs. 64.8%, p=0.319) and OS (66.2% vs. 70.4%, p=0.703) rates between the two groups. Conclusion The results suggest that fluoropyrimidine-based adjuvant therapy is not indicated in stage I-III GBC patients who have undergone R0 resection.
Abstract
Purpose The purpose of this study is to assess the role of adjuvant therapy in stage I-III gallbladder cancer (GBC) patients who have undergone R0 resection. Materials and Methods Clinical data were collected on 441 consecutive patients who underwent R0 resection for stage I-III GBC. Eligible patients were classified into adjuvant therapy and surveillance only groups. Propensity score matching (PSM) between the two groups was performed, adjusting clinical factors. Results In total, 84 and 279 patients treated with adjuvant therapy and followed up with surveillance only, respectively, were included in the analysis. Before PSM, the 5-year relapse-free survival (RFS) rate was lower in the adjuvant therapy group than in the surveillance only group (50.8% vs. 74.8%, p < 0.001), although there was no statistically significant difference in the 5-year overall survival (OS) rate (66.2% vs. 79.5%, p=0.089). After the PSM, baseline characteristics became comparable and there were no differences in the 5-year RFS (50.8% vs. 64.8%, p=0.319) and OS (66.2% vs. 70.4%, p=0.703) rates between the two groups. Conclusion The results suggest that fluoropyrimidine-based adjuvant therapy is not indicated in stage I-III GBC patients who have undergone R0 resection.
참고문헌 (22)
- Siegel RL, "Cancer statistics, 2015", CA Cancer J Clin, 65, pp.5~29 (2015)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
- Lim H, "Prognostic factors in patients with gallbladder cancer after surgical resection : analysis of 279 operated patients", J Clin Gastroenterol, 47, pp.443~448 (2013)
- Gold DG, "Adjuvant therapy for gallbladder carcinoma : the Mayo Clinic Experience", Int J Radiat Oncol Biol Phys, 75, pp.150~155 (2009)
- Wang SJ, "Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer", J Clin Oncol, 26, pp.2112~2117 (2008)
- Cereda S, "Adjuvant treatment in biliary tract cancer: to treat or not to treat?", World J Gastroenterol, 18, pp.2591~2596 (2012)
- "NCCN Clinical Practice Guidelines in Oncology: hepatobiliary cancers" (2015)[URL]
- Cho SY, "Adjuvant chemoradiation therapy in gallbladder cancer", J Surg Oncol, 102, pp.87~93 (2010)
- Wang SJ, "Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer", J Clin Oncol, 29, pp.4627~4632 (2011)
- Nakamura M, "Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer", Anticancer Res, 34, pp.3125~3129 (2014)
- Takada T, "Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma", Cancer, 95, pp.1685~1695 (2002)
- Park HS, "Outcome of adjuvant therapy for gallbladder cancer", Oncology, 79, pp.168~173 (2010)
- Horgan AM, "Adjuvant therapy in the treatment of biliary tract cancer : a systematic review and meta-analysis", J Clin Oncol, 30, pp.1934~1940 (2012)
- Ma N, "Adjuvant therapy in the treatment of gallbladder cancer : a meta-analysis", BMC Cancer, 15, pp.615~ (2015)
- Austin PC, "An introduction to propensity score methods for reducing the effects of confounding in observational studies", Multivariate Behav Res, 46, pp.399~424 (2011)
- Kayahara M, "Recent trends of gallbladder cancer in Japan : an analysis of 4, 770 patients", Cancer, 110, pp.572~580 (2007)
- Fong Y, "Evidence-based gallbladder cancer staging : changing cancer staging by analysis of data from the National Cancer Database", Ann Surg, 243, pp.767~771 (2006)
- Valle J, "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer", N Engl J Med, 362, pp.1273~1281 (2010)
- Yamanaka K, "A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer", Int J Clin Oncol, 19, pp.485~489 (2014)
- Ben-Josef E, "SWOG S0809 : a Phase II Intergroup Trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma", J Clin Oncol, 33, pp.2617~2622 (2015)
- Murakami Y, "Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection", J Gastrointest Surg, 15, pp.1007~1016 (2011)
- Murakami Y, "Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma", Ann Surg Oncol, 18, pp.651~658 (2011)